Jiangsu Nhwa Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 28.06%

Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has an Asset Resilience Ratio of 28.06% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Jiangsu Nhwa Pharmaceutical Co Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥2.71 Billion
≈ $395.97 Million USD Cash + Short-term Investments

Total Assets

CN¥9.64 Billion
≈ $1.41 Billion USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Jiangsu Nhwa Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 002262 net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Jiangsu Nhwa Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002262 company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥2.71 Billion 28.06%
Total Liquid Assets CN¥2.71 Billion 28.06%

Asset Resilience Insights

  • Very High Liquidity: Jiangsu Nhwa Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 28.06% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Jiangsu Nhwa Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jiangsu Nhwa Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
SIMCERE PHARMAC. GRP LTD
F:S2P
Drug Manufacturers - Specialty & Generic 0.44%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Jiangsu Nhwa Pharmaceutical Co Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Jiangsu Nhwa Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 27.85% CN¥2.57 Billion
≈ $375.93 Million
CN¥9.22 Billion
≈ $1.35 Billion
-0.26pp
2024-12-31 28.12% CN¥2.37 Billion
≈ $347.24 Million
CN¥8.44 Billion
≈ $1.24 Billion
+9.90pp
2023-12-31 18.22% CN¥1.33 Billion
≈ $195.35 Million
CN¥7.33 Billion
≈ $1.07 Billion
-4.19pp
2022-12-31 22.40% CN¥1.45 Billion
≈ $212.47 Million
CN¥6.48 Billion
≈ $948.40 Million
+3.83pp
2021-12-31 18.58% CN¥1.06 Billion
≈ $154.88 Million
CN¥5.70 Billion
≈ $833.68 Million
+1.18pp
2020-12-31 17.39% CN¥837.00 Million
≈ $122.48 Million
CN¥4.81 Billion
≈ $704.17 Million
+15.73pp
2019-12-31 1.67% CN¥70.00 Million
≈ $10.24 Million
CN¥4.20 Billion
≈ $614.81 Million
-1.68pp
2018-12-31 3.35% CN¥135.00 Million
≈ $19.75 Million
CN¥4.03 Billion
≈ $590.13 Million
-6.83pp
2017-12-31 10.18% CN¥336.05 Million
≈ $49.17 Million
CN¥3.30 Billion
≈ $483.12 Million
+6.14pp
2016-12-31 4.03% CN¥120.00 Million
≈ $17.56 Million
CN¥2.97 Billion
≈ $435.32 Million
--
pp = percentage points

About Jiangsu Nhwa Pharmaceutical Co Ltd

SHE:002262 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.78 Billion
CN¥18.99 Billion CNY
Market Cap Rank
#5263 Global
#1001 in China
Share Price
CN¥18.69
Change (1 day)
-0.11%
52-Week Range
CN¥18.69 - CN¥28.92
All Time High
CN¥31.19
About

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin… Read more